Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day—A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia
In this study, paliperidone ER 1.5 mg did not demonstrate efficacy in patients with acute schizophrenia. A markedly high placebo response was noted. Assay sensitivity with the 6 mg dose was not established. Paliperidone ER 1.5 mg was generally tolerable with a safety profile comparable to placebo.
Authors
- Joseph Palumbo
- Jaskaran Singh (ORCID: https://orcid.org/0000-0001-8466-0994)
- Rama Melkote
- Danielle Coppola
- Srihari Gopal (ORCID: https://orcid.org/0000-0001-5254-2192)
- Caroline Lannie
- Isaac Nuamah
- David M. Hough
Institutions
- Johnson & Johnson (United States) (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4064
- Citations
- 14
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.41